Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products.
$10.28+6.20%
报价 2026-11-06
市值
$545.7M
EV
$535.8M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -38.1%
$0.88$16.60
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ANLAdlai Nortye Ltd. | $545.7M | +6.2% | – | 100% | – | – | – | |
| BCAXBicara Therapeutics Inc. Common Stock | $572.4M | +5.6% | – | 0% | – | – | – | |
| FTHFaeth Therapeutics, Inc. | $568.4M | +10.7% | – | 0% | – | – | – | |
| OVIDOvid Therapeutics Inc. | $556.6M | +10.5% | -97.0% | 100% | – | – | – | |
| HELPCybin Inc. Common Stock | $555.4M | +6.8% | – | 0% | – | – | – | |
| ENTXEntera Bio Ltd. | $546.1M | +5.0% | – | 0% | – | – | – | |
| SLBTHorizon Space Acquisition II Corp. | $525.7M | +4.2% | – | 35.3% | – | – | – | |
| VALNValneva SE | $524.2M | -2.3% | – | 29.5% | – | – | – | |
| CAPRCapricor Therapeutics, Inc. | $521.2M | +4.7% | +18885.7% | 0% | – | 0.5x | – | |
| 同行中位数 | – | – | +9394.4% | 0% | – | 0.5x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。